Literature DB >> 1138157

Serum lipids in acromegaly.

E A Nikkilä, R Pelkonen.   

Abstract

Serum cholesterol and triglyceride concentrations were determined in 46 patients with active acromegaly but with otherwise intact pituitary function. The mean serum-cholesterol level of the patients was lower and the mean serum-triglyceride higher than in the basic population of comparable age. The incidence of hypercholesterolemia was similar to that in general population, whereas the incidence of type IV hypertriglyceridemia was almost three times higher than in control population. The serum triglyceride level was not related to relative body weight, basal serum growth hormone, or insulin concentrations, nor did it correlate with glucose tolerance or with plasma-insulin response to oral glucose. However, the patients with highest plasma-insulin response had significantly higher serum triglyceride than the rest of the acromegalic group. The endogenous serum-triglyceride turnover rate showed no consistent changes, but increased serum triglyceride was associated with increased production rate. Upon successful surgical treatment of the acromegaly, serum-triglyceride level decreased in most of the cases who initially had hypertriglyceridemia. It is concluded that acromeagaly can give rise to moderate secondary hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138157     DOI: 10.1016/0026-0495(75)90129-8

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  11 in total

Review 1.  Therapy of diabetes and dyslipidemia in acromegaly.

Authors:  G Tamburrano; C Durante; R Baldelli
Journal:  Pituitary       Date:  2002-01       Impact factor: 4.107

Review 2.  Insulin-like growth factor I: an attractive option for chronic heart failure?

Authors:  M Y Donath; J Zapf
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 3.923

Review 3.  Familial dyslipidaemias: an overview of genetics, pathophysiology and management.

Authors:  Sahar B Hachem; Arshag D Mooradian
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.

Authors:  Patricia Hernandez; Neena Passi; Taher Modarressi; Vivek Kulkarni; Meshal Soni; Fran Burke; Archna Bajaj; Daniel Soffer
Journal:  Curr Atheroscler Rep       Date:  2021-09-13       Impact factor: 5.113

Review 5.  Medical consequences of acromegaly: what are the effects of biochemical control?

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Mariano Galdiero; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

6.  Gene expression in skeletal muscle after an acute intravenous GH bolus in human subjects: identification of a mechanism regulating ANGPTL4.

Authors:  Berthil F F Clasen; Thomas Krusenstjerna-Hafstrøm; Mikkel Holm Vendelbo; Kasper Thorsen; Carlos Escande; Niels Møller; Steen B Pedersen; Jens Otto L Jørgensen; Niels Jessen
Journal:  J Lipid Res       Date:  2013-04-20       Impact factor: 5.922

7.  Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency.

Authors:  Maria Claudia Peixoto Cenci; Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Vera Aleta Mansur; Jaime Gold; Eduardo Michmacher; Mario Vaisman; Flávia Lúcia Conceição
Journal:  Pituitary       Date:  2009-04-24       Impact factor: 4.107

8.  Biological effects of Spirometra erinacei plerocercoids in several species of rodents.

Authors:  K Hirai; K Shiwaku; T Tsuboi; M Torii; H Nishida; Y Yamane
Journal:  Z Parasitenkd       Date:  1983

Review 9.  Acromegalic cardiomyopathy: a review of the literature.

Authors:  M P Matta; P Caron
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 10.  How safe is the treatment of uraemic children with recombinant human growth hormone?

Authors:  B Tönshoff; U Heinrich; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.